Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.
Publisher’s analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.
For more information about this report: http://www.reportsweb.com/global-cystic-fibrosis-therapeutics-market-2016-2020
Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2016-2020. The report has taken into consideration the revenue generated by the vendors in the PET packaging market for packaging of different goods.
The market is divided into the following segments based on geography:
Publisher’s report, Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
-F. Hoffmann-La Roche
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001427421/sample
Other prominent vendors
-Advanced Inhalation Therapies (AIT)
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001427421/buying